Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
about
Glioblastoma cancer stem cells: Biomarker and therapeutic advancesUnveiling YKL-40, from Serum Marker to Target Therapy in GlioblastomaNovel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim.Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors.Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1.Wnt activation promotes neuronal differentiation of glioblastomaThe anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway.Isolation of cancer stem cells from three human glioblastoma cell lines: characterization of two selected clones.Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.Expression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells.ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarraysAutocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cellsHIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathwayGlioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs.Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles.Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Emerging targets for glioblastoma stem cell therapyDigital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survivalEpigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5ANovel association between microglia and stem cells in human gliomas: A contributor to tumour proliferation?Label-retaining assay enriches tumor-initiating cells in glioblastoma spheres cultivated in serum-free medium.Essential gene pathways for glioblastoma stem cells: clinical implications for prevention of tumor recurrence.Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Peptide vaccines for the treatment of glioblastoma.Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target.Therapeutic antibodies against cancer stem cells: a promising approach.A comprehensive profile of recurrent glioblastoma.CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.
P2860
Q26859782-D2632CE8-BA6F-4AA4-AB80-8EE5D31E448DQ26998561-B8EBB02F-DEAF-4049-BB7C-935A33BBBBCEQ30413140-5A524F45-294A-4C49-98E2-EA6FF6995419Q30997872-3C49FE95-1894-42D5-A818-2F7BD18DE115Q33580112-D6568FFE-3C6C-4BF1-AC9B-D834229F92CFQ33903166-E7D83F16-BCEE-42B8-AEB8-9D64AC197801Q34046737-00CB411C-6EA5-4240-BE35-5F724094B5E5Q34047392-525E0185-2A45-4E9D-B83E-A4D43CC288BAQ34184430-80616AE3-03CA-4DD6-B0B9-EFF3DF82DC1BQ34720622-B17F4403-8AA9-4DFB-A311-A520F747FB36Q34723950-1AC92ADB-3713-453A-9337-942458229316Q35048997-87F572B3-B80A-4251-9280-456920654833Q35060849-E7235A69-D399-42BB-A15C-584C55DA712DQ35631598-6A0EC62B-33AA-47E4-A238-6F3720B0C203Q35687115-017EBA11-3B95-4C5D-BDC6-242E8097A043Q35794896-C8C67E68-34F0-49AB-B3DD-825976146485Q35823287-06E99F20-A87F-4B73-A0B7-03B157F7CEE1Q36061775-6C40789A-FFCC-4BA0-9E42-069BBA77CEDDQ36259173-D3E94380-65CF-47E8-A55A-6D2AA37108D0Q36280796-16147788-3A95-4D53-98EB-191065B1FCA4Q36502009-87219EAD-5C5C-46CD-82C2-0D490B9CDFDAQ36566768-C751215D-D0AA-40FA-B03F-A20A389640E8Q36586507-2D8E8CA9-7B7C-4CAA-A7E3-8B473A91E3FFQ36588945-0BA4117B-00D5-4D39-A15F-9087E017D7E3Q36850429-DEA49CC6-18FE-435A-A602-827E1BF4F56EQ36873852-BC74F897-5DDB-4539-AE7D-439DB2765646Q37106630-21FE69AB-7A90-4112-808F-627D1982AE97Q37132697-393D601F-0137-412B-9682-35813110B26DQ37658825-21B2D43D-5E56-4BA5-A888-B714C49234A3Q37705532-7DFB61A7-CCBD-4CC2-B34B-AA33D7DC6289Q37887286-E82C7463-E805-45BD-9CF2-5436958C2712Q38066416-94550D12-8E48-4D2C-B97A-1496DB988FAAQ38180344-25DED940-CA3A-444B-83D6-F8C0D98B69B9Q38285889-835B6B30-E0FE-4354-89D3-EC12291F3047Q38287518-06AD98F2-ECF6-4484-8AD4-C0FE73236062Q38637435-5BC2253A-AEAB-4CC6-A2EC-59A21C21336BQ38797345-A5287293-379F-410C-966A-ECC5E79819C3Q38893170-B3039732-2577-4896-84B0-C60F49909C93Q38943301-0D0573C1-1C75-4D45-8378-F8E3FCBC5A09Q38952768-9106344D-4D3A-411E-A5DA-9F51F85B8FA1
P2860
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@en
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@nl
type
label
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@en
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@nl
prefLabel
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@en
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@nl
P2093
P2860
P1476
Molecular properties of CD133+ ...... actory recurrent brain tumors.
@en
P2093
Cho-Lea Tso
David H Nguyen
Jason Y Liu
Jonathan L Tso
Kenneth Chung
Linda M Liau
On Ying Liu
Paul S Mischel
Peter Shitaku
Qinghai Liu
P2860
P2888
P356
10.1007/S11060-009-9919-Z
P577
2009-05-26T00:00:00Z